Jessica Grossman, IgGenix CEO
IgGenix sprints to clinic with peanut allergy candidate and additional $40M
A small, Eli Lilly-backed biotech has received $40 million on its way to the clinic with a self-administered injection for peanut allergies.
IgGenix unveiled a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
